209 related articles for article (PubMed ID: 32623849)
1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients.
Macías M; Cañada-Higueras E; Alegre E; Bielsa A; Gracia J; Patiño-García A; Ferrer-Costa R; Sendino T; Andueza MP; Mateos B; Rodríguez J; Corral J; Gúrpide A; Lopez-Picazo JM; Perez-Gracia JL; Gil-Bazo I; Alkorta-Aranburu G; González Á
Clin Chem Lab Med; 2020 Jul; 58(8):1341-1348. PubMed ID: 32623849
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
4. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
5. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
6. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.
Mehrotra M; Singh RR; Chen W; Huang RSP; Almohammedsalim AA; Barkoh BA; Simien CM; Hernandez M; Behrens C; Patel KP; Routbort MJ; Broaddus RR; Medeiros LJ; Wistuba II; Kopetz S; Luthra R
J Mol Diagn; 2017 Jul; 19(4):514-524. PubMed ID: 28506684
[TBL] [Abstract][Full Text] [Related]
7. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
[TBL] [Abstract][Full Text] [Related]
8. Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.
Herrmann S; Zhan T; Betge J; Rauscher B; Belle S; Gutting T; Schulte N; Jesenofsky R; Härtel N; Gaiser T; Hofheinz RD; Ebert MP; Boutros M
Mol Oncol; 2019 Aug; 13(8):1669-1683. PubMed ID: 31254442
[TBL] [Abstract][Full Text] [Related]
9. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
10. From cfDNA to Sequencing: Workflows and Potentials.
Tebaldi M; Salvi S
Methods Mol Biol; 2019; 1909():119-125. PubMed ID: 30580427
[TBL] [Abstract][Full Text] [Related]
11. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
13. Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends.
Devereaux KA; Souers RJ; Merker JD; Lindeman NI; Graham RP; Hameed MR; Vasalos P; Moncur JT; Lockwood CM; Xian RR
Arch Pathol Lab Med; 2023 Apr; 147(4):425-433. PubMed ID: 35687785
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
16. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
17. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
Barata PC; Koshkin VS; Funchain P; Sohal D; Pritchard A; Klek S; Adamowicz T; Gopalakrishnan D; Garcia J; Rini B; Grivas P
Ann Oncol; 2017 Oct; 28(10):2458-2463. PubMed ID: 28945843
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome.
Palmieri M; Pinto AM; di Blasio L; Currò A; Monica V; Sarno LD; Doddato G; Baldassarri M; Frullanti E; Giliberti A; Mussolin B; Fallerini C; Molinaro F; Vaghi M; Renieri A; Primo L
Vascular; 2021 Feb; 29(1):85-91. PubMed ID: 32588787
[TBL] [Abstract][Full Text] [Related]
20. Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.
Kim B; Kim Y; Cho JY; Lee KA
Ann Lab Med; 2024 Mar; 44(2):164-173. PubMed ID: 37903652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
